Prices delayed by at least 15 minutes | Prices updated on 23 May 2025, 18.22 BST | Print
Immupharma PLC (IMM)
ORD 1PThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Company profile
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.
Address
One Bartholomew Close
London
GBR
EC1A 7BL
Telephone
+44 2071524080
Major shareholders
| Name | Amount | Holding (%) |
|---|---|---|
| Lanstead Capital LP | 80,590,404 | 16.13 |
| Robert henri Zimmer | 27,344,514 | 6.57 |
| Luca and Associates AG | 22,000,000 | 5.28 |
Key personnel
| Name | Position |
|---|---|
| Dr. Franco Di Muzio | Non-Executive Director |
| Mr. Timothy Paul McCarthy | Executive Director,Chairman and Chief Executive Officer |
| Mr. Dimitri Dimitriou | Executive Director,Chief Executive Officer |
| Dr. Sanjeev Pandya | Non-Executive Director,Senior Independent Director |
| Dr. Stephane Robert George Mery | Non-Executive Director |
| Dr. Timothy Gary Franklin | Executive Director,Chief Operating Officer |
| Ms. Lisa Baderoon | Non-Executive Director,Head of Investor Relations |
| Dr. Robert Reilly Laurence | Non-Executive Director,Senior Independent |
| Dr. Sebastien R. Goudreau | Non-Executive Director |
Forecast key dates
| Name | Key Date |
|---|---|
| ImmuPharma PLC Fourth Quarter Earnings Results for 2025 | 19/05/2026 |
| ImmuPharma PLC Annual Report for 2025 | 19/05/2026 |
| ImmuPharma PLC Second Quarter Earnings Results for 2025 | 09/09/2025 |
| ImmuPharma PLC Annual General Meeting for 2024 | 12/06/2025 |
| ImmuPharma PLC Fourth Quarter Earnings Results for 2024 | 19/05/2025 |
| ImmuPharma PLC Annual Report for 2024 | 19/05/2025 |
Previous key dates
| Name | Key Date |
|---|---|
| ImmuPharma PLC Fourth Quarter Earnings Results for 2024 | 19/05/2025 |
| ImmuPharma PLC Annual Report for 2024 | 19/05/2025 |
| ImmuPharma PLC Second Quarter Earnings Results for 2024 | 09/09/2024 |
| ImmuPharma PLC Annual General Meeting for 2023 | 28/06/2024 |
| ImmuPharma PLC Fourth Quarter Earnings Results for 2023 | 05/06/2024 |
| ImmuPharma PLC Annual Report for 2023 | 05/06/2024 |
Activity analysis
| 2022 Turnover (£) | |
|---|---|
| Single Segment | 3.97 mn |
| Total | 3.97 mn |
Geographical analysis
| 2022 Turnover (£) | |
|---|---|
| France | -0.55 mn |
| Switzerland | -0.00 mn |
| United Kingdom | -2.27 mn |
| Total | -2.82 mn |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.